Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use
Completed · Phase 1
Conditions studied: Allergic Reactions
In brief
The purpose of this study is to determine if Valortim, or one or more of its selected formulation components, induces a wheal reaction when introduced percutaneously. Two of 4 subjects dosed in a previous study with a modified formulation of Valortim experienced treatment related adverse events which were suggestive of allergic or allergic-like reactions. In order to better characterize these reactions and determine if they represent allergic or allergic-like reactions to Valortim or one or more of its components, skin testing of Valortim and selected components on naïve and Valortim-exposed subjects will be performed in this study
Key facts
- Study ID
- NCT01204866
- Run by
- PharmAthene, Inc.
- People needed
- 5
- Starts
- 2010-07-01
- Expected to finish
- 2010-09-01
- Last updated by the study team
- 2010-09-24
Who can join
Age: 18 and older, up to 59. Sex: any. Healthy volunteers: accepted.
Where it is running
- Kansas City Allergy and Asthma — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.